Last updated: September 2, 2026
Gilead Sciences’ Vosevi is a three-drug, once-daily hepatitis C virus treatment combining sofosbuvir, velpatasvir, and voxilaprevir. Its commercial role is narrower than Epclusa or Mavyret because Vosevi is primarily used for patients who failed prior direct-acting antiviral therapy. The product has maintained roughly half-billion-dollar annual sales despite a shrinking hepatitis C market, supported by its position as a high-value retreatment regimen.
Vosevi’s principal long-term risks are declining hepatitis C prevalence, increased use of lower-cost generic regimens, payer control, and eventual erosion of composition and combination patent protection. Biosimilar competition is irrelevant because Vosevi is a chemically synthesized small molecule, but abbreviated new drug application, or ANDA, competition could materially affect pricing after relevant patents and regulatory exclusivity expire.
What is Vosevi and how does the three-drug regimen work?
Vosevi contains:
| Active ingredient |
Drug class |
Primary role |
| Sofosbuvir |
Nucleotide NS5B polymerase inhibitor |
Blocks viral RNA replication |
| Velpatasvir |
NS5A inhibitor |
Inhibits viral replication and assembly |
| Voxilaprevir |
NS3/4A protease inhibitor |
Blocks viral polyprotein processing |
The FDA approved Vosevi in July 2017 for adults with chronic hepatitis C genotype 1 through 6 infection. The approved use includes patients who previously received an NS5A inhibitor and patients with genotype 1 through 6 infection who previously received a sofosbuvir-containing regimen without an NS5A inhibitor.[1]
Vosevi is generally administered for 12 weeks. Its clinical value is concentrated in treatment-experienced patients, particularly those with prior virologic failure or resistance-associated substitutions that limit reuse of earlier regimens.
How large is the Vosevi and hepatitis C market?
The hepatitis C market is mature and contracting in developed countries. Most commercially attractive patients can be cured with 8- to 12-week direct-acting antiviral therapy, which reduces the pool of untreated patients and limits chronic refill revenue.
The market remains substantial because of:
- Undiagnosed infections.
- Reinfection among people who inject drugs.
- Treatment gaps in Medicaid and other public programs.
- Limited access in low- and middle-income countries.
- Patients who fail prior direct-acting antiviral therapy.
- Late diagnosis among people with advanced liver disease.
The United States remains the most important high-value market, but public-health treatment volumes depend heavily on payer restrictions, screening programs, and state-level Medicaid policies. International markets have greater patient volume but lower net pricing.
How does Vosevi compare with Epclusa and Mavyret?
| Product |
Company |
Active ingredients |
Typical commercial role |
Competitive position |
| Vosevi |
Gilead |
Sofosbuvir/velpatasvir/voxilaprevir |
Retreatment after prior direct-acting antiviral failure |
Premium salvage product |
| Epclusa |
Gilead |
Sofosbuvir/velpatasvir |
Broad first-line treatment across genotypes 1-6 |
Major branded and generic competitor |
| Mavyret |
AbbVie |
Glecaprevir/pibrentasvir |
Broad first-line treatment, often shorter duration |
Strong price and duration competitor |
| Harvoni |
Gilead |
Ledipasvir/sofosbuvir |
Earlier genotype 1 treatment |
Mature and heavily eroded |
| Zepatier |
Merck |
Elbasvir/grazoprevir |
Genotype-specific treatment |
Declining commercial relevance |
Vosevi is not a direct substitute for every Epclusa or Mavyret prescription. Physicians generally reserve it for retreatment, which reduces volume but supports clinical differentiation and limits direct price comparison.
What has been the financial trajectory of Vosevi?
Vosevi has developed into a durable specialty product rather than a mass-market HCV franchise. Gilead’s annual reports indicate that Vosevi sales have remained approximately in the several-hundred-million-dollar range annually, generally near or above $500 million in recent reporting periods, while total HCV franchise revenue has declined over time.[2-5]
| Financial factor |
Effect on Vosevi |
| Retreatment demand |
Supports stable utilization |
| Declining diagnosed HCV population |
Limits long-term growth |
| Higher clinical complexity |
Supports premium positioning |
| Generic sofosbuvir and velpatasvir access |
Pressures first-line alternatives more than Vosevi initially |
| Payer rebates and government purchasing |
Reduces net price |
| International licensing |
Expands access but lowers revenue per patient |
| Curative treatment |
Prevents recurring chronic-drug revenue |
Vosevi has benefited from an unusual market structure. The overall HCV market is shrinking, but the product is concentrated in patients for whom treatment failure carries high clinical and economic costs. This supports revenue stability even as broad first-line therapy volumes decline.
Gilead’s HCV sales mix has shifted toward products with differentiated retreatment or pan-genotypic utility. Epclusa remains the larger franchise product, while Vosevi contributes a smaller but strategically important revenue stream. The product is unlikely to become a major growth engine without expanded diagnosis, treatment uptake, or new indications.
When does Vosevi lose regulatory exclusivity?
Vosevi received FDA approval in 2017. Its principal new-drug approval exclusivity period was three years for the new combination, subject to the scope of the approved application and applicable FDA exclusivity rules.[1][6]
The practical exclusivity picture is more important than the three-year regulatory period:
| Exclusivity element |
Commercial effect |
| New combination exclusivity |
Restricted certain ANDA approvals during the applicable period |
| Ingredient and formulation patents |
Can delay generic approval or launch |
| Method-of-use protection |
May affect labeled use but usually has limited ability to block all generic substitution |
| Pediatric exclusivity |
Could add six months if granted for qualifying studies |
| Patent litigation |
Can delay or accelerate generic entry depending on settlement terms |
Because Vosevi contains previously approved active ingredients, regulatory exclusivity alone does not provide the principal commercial barrier. Patent protection, settlement agreements, and the ability of a generic applicant to avoid infringing listed claims are more important.
What patents protect sofosbuvir, velpatasvir, and voxilaprevir?
The Vosevi estate is built from several layers:
- Patents covering sofosbuvir and related nucleotide prodrug technology.
- Patents covering velpatasvir and NS5A inhibitor compounds.
- Patents covering voxilaprevir and NS3/4A protease inhibitor compounds.
- Combination patents covering the coadministration or formulation of the three active ingredients.
- Manufacturing, crystalline-form, salt, and pharmaceutical-composition patents.
- Method-of-use patents covering treatment of particular genotypes or previously treated populations.
Representative U.S. patent families associated with the active ingredients and combination technology include patents in the US 8,815,253, US 9,365,531, US 9,393,281, and US 9,670,281 families. The applicable scope and expiration dates differ by patent, continuation, terminal disclaimer, patent-term adjustment, and any pediatric extension.[7-10]
What are the likely patent expiration dates?
The core sofosbuvir patent estate has been publicly associated with expiration around the end of the 2020s, including potential pediatric-extension effects. Velpatasvir and voxilaprevir composition and combination patents extend into the early 2030s in certain U.S. families. Some secondary patents may expire later, but their ability to block an all-ingredient generic depends on claim scope and validity.
| Patent layer |
Indicative U.S. timing |
Risk implication |
| Core sofosbuvir protection |
Around 2029-2030 |
Earlier risk for sofosbuvir-containing products |
| Velpatasvir compound and formulation protection |
Early 2030s in relevant families |
Protects key Vosevi and Epclusa technology |
| Voxilaprevir compound and combination protection |
Early 2030s in relevant families |
Central barrier to a full Vosevi copy |
| Secondary formulation or manufacturing claims |
Potentially later |
May create litigation leverage but may not block all entry |
The Orange Book remains the controlling source for patents listed against the Vosevi NDA and for current expiration dates. Patent-family expiration should not be treated as equivalent to a guaranteed market exclusivity date because ANDA applicants may challenge individual patents, carve out uses, or launch after partial invalidation.[6]
Are there Paragraph IV challenges to Vosevi?
No widely reported Paragraph IV challenge has produced a major generic Vosevi launch in the U.S. market through the latest broadly available public reporting period. The absence of a launch does not eliminate risk. ANDA applicants can challenge listed patents privately, file certification strategies that do not immediately produce public litigation, or target individual components rather than the full three-drug product.
A Vosevi Paragraph IV case would likely focus on:
- Anticipation or obviousness of the combination.
- Written description and enablement.
- Patent-term calculations.
- Whether listed patents claim the approved product or only a narrower use.
- Noninfringement based on formulation or manufacturing differences.
- Validity of voxilaprevir and velpatasvir compound claims.
The largest near-term generic threat is more likely to arise from individual-component products, especially generic sofosbuvir/velpatasvir, than from a direct Vosevi equivalent. Those products can reduce prescribing of branded HCV regimens and weaken the overall price architecture even if they do not immediately substitute for salvage therapy.
What is the Orange Book status of Vosevi?
Vosevi is an FDA-approved small-molecule drug listed in the Orange Book under its NDA. Its regulatory protection is therefore assessed through traditional NDA, patent-listing, and ANDA rules rather than the biologics license application and biosimilar framework.[6]
The relevant Orange Book questions are:
- Which patents are currently listed for NDA 209195?
- Which patents have unexpired claims?
- Are any patents subject to pediatric exclusivity?
- Has an ANDA applicant filed a Paragraph IV certification?
- Is the applicant seeking approval for all indications or using a section viii statement to omit a patented use?
- Are listed patents directed to the product, formulation, or method of use?
A generic manufacturer could attempt to design around formulation or method-of-use claims while retaining the same active ingredients. That strategy would make the scope of the remaining composition claims particularly important.
Is there biosimilar risk for Vosevi?
Vosevi has no biosimilar risk because it is a chemically synthesized small-molecule combination tablet. The relevant competitors are generic drugs approved through ANDAs, not biosimilars approved under the Public Health Service Act.
Potential generic pathways include:
- A direct three-active-ingredient tablet.
- Separate tablets prescribed together.
- Generic sofosbuvir/velpatasvir combinations that compete with portions of the treatment pathway.
- Products targeting retreatment uses after patent expiry or settlement-based entry.
A direct generic Vosevi product would need to establish pharmaceutical equivalence and bioequivalence, while its label and patent certifications would determine the timing of approval and launch.
What licensing deals affect sofosbuvir and Vosevi economics?
Gilead has used licensing and voluntary access arrangements for hepatitis C products, particularly sofosbuvir and velpatasvir, through agreements involving the Medicines Patent Pool and generic manufacturers in selected lower-income countries.[11]
These arrangements have three commercial effects:
- They increase treatment access and support public-health elimination programs.
- They create lower-priced generic competition outside major high-income markets.
- They preserve branded pricing and patent control in territories excluded from the licenses.
The resulting geography is segmented. High-income markets retain greater brand value and patent enforcement, while many lower-income markets rely on licensed generic products. Vosevi’s commercial opportunity in licensed territories is therefore limited, but access agreements can increase use of the underlying molecules.
What manufacturing and intellectual-property barriers protect Vosevi?
Manufacturing barriers are less durable than compound patents but can delay competition. They may include:
- Stereoselective synthesis of antiviral intermediates.
- Complex prodrug chemistry for sofosbuvir.
- Control of impurity profiles.
- Solid-state and polymorph control.
- Multi-active-ingredient tablet compatibility.
- Stability and dissolution requirements.
- Specialized analytical methods.
Sofosbuvir production has historically involved substantial process know-how, but generic manufacturers have developed commercial routes in licensed markets. Manufacturing complexity is therefore a secondary barrier. The strongest protection remains the composition and combination patent estate, particularly claims covering voxilaprevir and the specific three-drug regimen.
What generic launch scenarios exist for Vosevi?
Scenario 1: No direct generic launch before the early 2030s
This outcome would preserve Vosevi’s premium retreatment position. Gilead could continue to earn several hundred million dollars annually, with gradual erosion caused by lower HCV prevalence and payer pressure.
Scenario 2: Early launch after patent settlement
A settlement could permit one or more generic manufacturers to launch on a negotiated date before the latest patent expiry. Market share would likely shift quickly because HCV treatment is curative and payers have strong incentives to prefer lower-cost products.
Scenario 3: Component-level erosion
Generic sofosbuvir/velpatasvir products could reduce first-line branded demand without directly replacing Vosevi in every retreatment case. This would pressure Gilead’s broader HCV franchise and could gradually reduce physician familiarity with branded regimens.
Scenario 4: Patent invalidation or successful design-around
A successful challenge to a key compound or combination patent could enable a direct generic product earlier than expected. The commercial impact would be substantial because Vosevi has no chronic refill cycle to offset price erosion.
How strong is the Vosevi patent estate?
The estate is strongest where it combines active-ingredient claims with a specific approved combination and a clinically differentiated retreatment indication. It is weaker where protection depends only on narrow formulation, manufacturing, or method-of-use claims.
| Strength factor |
Assessment |
| Clinical differentiation |
Strong in retreatment |
| Composition protection |
Potentially strong through early 2030s |
| Regulatory exclusivity |
Limited relative to patent protection |
| Manufacturing barriers |
Moderate |
| Generic substitution pressure |
High after core patents expire |
| Biosimilar protection |
Not applicable |
| Settlement leverage |
Dependent on validity and remaining patent term |
The key business question is whether a generic can enter with all three active ingredients while avoiding or invalidating the remaining composition patents. If the answer is yes, Vosevi revenue could decline sharply within a single contracting cycle.
What patent litigation and settlements affect Vosevi?
The most commercially relevant litigation has involved Gilead’s broader HCV patent estate, especially sofosbuvir-related patents and licensing disputes. Litigation involving one active ingredient can influence Vosevi indirectly because sofosbuvir is a mandatory component of the product.
Settlement agreements in the HCV sector have historically used territory-specific launch dates and authorized-generic structures. Such agreements can preserve significant value in the United States while allowing earlier generic access in selected markets. Publicly available information does not indicate a major U.S. Vosevi settlement that has established an earlier direct-generic launch date.
What is the geographic coverage and market outlook?
Vosevi’s highest revenue potential remains in the United States, Japan, and selected European markets. Price and access vary sharply by geography.
| Region |
Market characteristic |
Vosevi outlook |
| United States |
High price, managed access, retreatment demand |
Largest revenue pool |
| Europe |
Tendering and reference pricing |
Lower net price, stable clinical use |
| Japan |
Regulated pricing and HCV treatment programs |
Moderate value |
| Lower-income markets |
Licensed generics and public procurement |
High volume, low branded revenue |
| Emerging markets |
Diagnosis and access constraints |
Long-term volume opportunity |
The World Health Organization’s goal of eliminating hepatitis C as a public-health threat by 2030 supports diagnosis and treatment expansion, but it also implies a declining addressable population after successful elimination programs.[12]
Key Takeaways
- Vosevi is Gilead’s premium retreatment product for chronic hepatitis C.
- The product combines sofosbuvir, velpatasvir, and voxilaprevir in a once-daily 12-week regimen.
- Revenue has remained approximately in the several-hundred-million-dollar annual range despite overall HCV market contraction.
- Epclusa and Mavyret are the principal commercial competitors, but Vosevi is differentiated by its retreatment role.
- Vosevi faces ANDA competition, not biosimilar competition.
- Core sofosbuvir protection is associated with expiration around 2029-2030, while relevant velpatasvir and voxilaprevir protection extends into the early 2030s in certain patent families.
- No major direct-generic Vosevi launch has been broadly reported through the latest public reporting period.
- Generic component products pose a broader franchise threat before a direct Vosevi copy reaches the market.
- A successful challenge to a key compound or combination patent could cause rapid revenue erosion because treatment is curative and patients do not generate recurring refill demand.
- The principal financial outlook is gradual decline, interrupted by possible stabilization from retreatment demand and expanded diagnosis.
FAQs
Is Vosevi more valuable than Epclusa?
No. Epclusa has the broader treatment population and larger commercial franchise. Vosevi has greater strategic value in retreatment because it addresses patients who failed earlier direct-acting antiviral therapy.
Can patients use generic sofosbuvir and velpatasvir instead of Vosevi?
Not in every case. Generic sofosbuvir/velpatasvir may be appropriate for treatment-naive patients, but patients with prior treatment failure may require a regimen containing voxilaprevir or another clinically appropriate salvage option.
Does Vosevi have composition-of-matter patent protection?
The active ingredients and related combination technology are protected by multiple patent families. The commercial strength of that protection depends on the specific claims listed for the Vosevi NDA and their remaining enforceable term.
What would happen to Vosevi sales after generic entry?
Sales would likely decline rapidly, particularly if a direct three-drug generic receives unrestricted substitution and payer-preferred status. Net price erosion would probably precede complete volume displacement.
Is Vosevi included in Gilead’s HIV business?
No. Vosevi is part of Gilead’s hepatitis C portfolio. Its financial performance is reported with Gilead’s HCV product sales rather than HIV product revenue.
References
- U.S. Food and Drug Administration. (2017). FDA approves new treatment for chronic hepatitis C virus infection.
- Gilead Sciences, Inc. (2021). 2020 annual report.
- Gilead Sciences, Inc. (2022). 2021 annual report.
- Gilead Sciences, Inc. (2023). 2022 annual report.
- Gilead Sciences, Inc. (2024). 2023 annual report.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Patent No. 8,815,253. (2014). Nucleotide analogues for the treatment of hepatitis C virus.
- U.S. Patent No. 9,365,531. (2016). Antiviral compounds and methods of use.
- U.S. Patent No. 9,393,281. (2016). Combinations of antiviral compounds.
- U.S. Patent No. 9,670,281. (2017). Antiviral compounds and pharmaceutical compositions.
- Medicines Patent Pool. (2024). Hepatitis C licensing and access programs.
- World Health Organization. (2023). Global health sector strategies on HIV, viral hepatitis and sexually transmitted infections, 2022-2030.
